|
1
|
Zhang Z and Lin CC: Taking advantage of
neural development to treat glioblastoma. Eur J Neurosci.
40:2859–2866. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Giese A, Bjerkvig R, Berens ME and
Westphal M: Cost of migration: invasion of malignant gliomas and
implications for treatment. J Clin Oncol. 21:1624–1636. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nielsen JS and McNagny KM: The role of
podocalyxin in health and disease. J Am Soc Nephrol. 20:1669–1676.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riccioni R, Calzolari A, Biffoni M, et al:
Podocalyxin is expressed in normal and leukemic monocytes. Blood
Cells Mol Dis. 37:218–225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kelley TW, Huntsman D, McNagny KM,
Roskelley CD and Hsi ED: Podocalyxin: a marker of blasts in acute
leukemia. Am J Clin Pathol. 124:134–142. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yasuoka H, Tsujimoto M, Hirokawa M, et al:
Podocalyxin expression in undifferentiated thyroid carcinomas. J
Clin Pathol. 61:1228–1229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsu YH, Lin WL, Hou YT, et al: Podocalyxin
EBP50 ezrin molecular complex enhances the metastatic potential of
renal cell carcinoma through recruiting Rac1 guanine nucleotide
exchange factor ARHGEF7. Am J Pathol. 176:3050–3061. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sizemore S, Cicek M, Sizemore N, Ng KP and
Casey G: Podocalyxin increases the aggressive phenotype of breast
and prostate cancer cells in vitro through its interaction with
ezrin. Cancer Res. 67:6183–6191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Somasiri A, Nielsen JS, Makretsov N, et
al: Overexpression of the anti-adhesin podocalyxin is an
independent predictor of breast cancer progression. Cancer Res.
64:5068–5073. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu H, Yang L, Liao D, Chen Y, Wang W and
Fang J: Podocalyxin regulates astrocytoma cell invasion and
survival against temozolomide. Exp Ther Med. 5:1025–1029.
2013.PubMed/NCBI
|
|
12
|
Kaprio T, Fermér C, Hagström J, Mustonen
H, Böckelman C, Nilsson O and Haglund C: Podocalyxin is a marker of
poor prognosis in colorectal cancer. BMC Cancer. 14:4932014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
De Gasparo M, Catt KJ, Inagami T, Wright
JW and Unger T: International union of pharmacology. XXIII. The
angiotensin II receptors. Pharmacol Rev. 52:415–472.
2000.PubMed/NCBI
|
|
14
|
Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y,
Li Q, Xiang Y and Gao B: Angiotensin-(1-7) inhibits the migration
and invasion of A549 human lung adenocarcinoma cells through
inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol
Rep. 27:783–790. 2012.
|
|
15
|
George AJ, Thomas WG and Hannan RD: The
renin angioten sin system and cancer: old dog, new tricks. Nat Rev
Cancer. 10:745–759. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Röcken C, Röhl FW, Diebler E, Lendeckel U,
Pross M, Carl-McGrath S and Ebert MP: The angiotensin
II/angiotensin II receptor system correlates with nodal spread in
intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev.
16:1206–1212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ferreira AJ, Murça TM, Fraga-Silva RA,
Castro CH, Raizada MK and Santos RA: New cardiovascular and
pulmonary therapeutic strategies based on the
angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor
axis. Int J Hypertens. 2012:1478252012.PubMed/NCBI
|
|
18
|
Raizada MK and Ferreira AJ: ACE2: a new
target for cardiovascular disease therapeutics. J Cardiovasc
Pharmacol. 50:112–119. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Der Sarkissian S, Huentelman MJ, Stewart
J, Katovich MJ and Raizada MK: ACE2: a novel therapeutic target for
cardiovascular diseases. Prog Biophys Mol Biol. 91:163–198. 2006.
View Article : Google Scholar
|
|
20
|
Rice GI, Thomas DA, Grant PJ, Turner AJ
and Hooper NM: Evaluation of angiotensin-converting enzyme (ACE),
its homologue ACE2 and neprilysin in angiotensin peptide
metabolism. Biochem J. 383:45–51. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ferreira AJ and Santos RA: Cardiovascular
actions of angiotensin-(1-7). Braz J Med Biol Res. 38:499–507.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gomes ER, Santos RA and Guatimosim S:
Angiotensin-(1-7)-mediated signaling in cardiomyocytes. Int J
Hypertens. 2012:4931292012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garcia-Espinosa MA, Lesser GJ, Debinski W,
Tallant EA and Gallagher PE: Angiotensin-(1-7), a peptide hormone
with therapeutic potential for the treatment of glioblastomas
(abstract). In: Proceedings of the 103rd Annual Meeting of the
American Association for Cancer Research; 2012 Mar 31-Apr 4;
Chicago, Illinois. Philadelphia (PA): AACR. Cancer Res. 72(Suppl
8): Abs 1938. 2012. View Article : Google Scholar
|
|
24
|
Gironacci MM, Adamo HP, Corradi G, Santos
RA, Ortiz P and Carretero OA: Angiotensin (1-7) induces MAS
receptor internalization. Hypertension. 58:176–181. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang B, Feng P, Xiao Z and Ren EC: LIM and
SH3 protein 1 (Lasp1) is a novel p53 transcriptional target
involved in hepatocellular carcinoma. J Hepatol. 50:528–537. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang
S, Wang W, Zhang J and Zhang Y: RNAi-mediated silencing of VEGF-C
inhibits non-small cell lung cancer progression by simultaneously
down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent
axes-induced ERK, p38 and AKT signalling pathways. Eur J Cancer.
47:2353–2363. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jo YK, Park SJ, Shin JH, Kim Y, Hwang JJ,
Cho DH and Kim JC: ARP101, a selective MMP-2 inhibitor, induces
autophagy-associated cell death in cancer cells. Biochem Biophys
Res Commun. 404:1039–1043. 2011. View Article : Google Scholar
|
|
28
|
Qazi H, Shi ZD and Tarbell JM: Fluid shear
stress regulates the invasive potential of glioma cells via
modulation of migratory activity and matrix metalloproteinase
expression. PLoS One. 6:e203482011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fekete A, Bőgel G, Pesti S, Péterfi Z,
Geiszt M and Buday L: EGF regulates tyrosine phosphorylation and
membrane-translocation of the scaffold protein Tks5. J Mol Signal.
8:82013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang N, Hui L, Wang Y, Yang H and Jiang X:
SOX2 promotes the migration and invasion of laryngeal cancer cells
by induction of MMP-2 via the PI3K/Akt/mTOR pathway. Oncol Rep.
31:2651–2659. 2014.PubMed/NCBI
|
|
31
|
Yoon SO, Shin S, Lee HJ, Chun HK and Chung
AS: Isoginkgetin inhibits tumor cell invasion by regulating
phosphatidylinositol 3-kinase/Akt-dependent matrix
metalloproteinase-9 expression. Mol Cancer Ther. 5:2666–2675. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Liao Q, Li K, Zhong D, Weng X and Mi
M: Knockdown of endothelin A receptor expression inhibits
osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse
model. Mol Med Rep. 5:1391–1395. 2012.PubMed/NCBI
|
|
33
|
Wegman-Ostrosky T, Soto-Reyes E,
Vidal-Millán S and Sánchez-Corona J: The renin-angiotensin system
meets the hallmarks of cancer. J Renin Angiotensin Aldosterone
Syst. Aug 9–2013.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Silva DM, Vianna HR, Cortes SF,
Campagnole-Santos MJ, Santos RAS and Lemos VS: Evidence for a new
angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley
rats. Peptides. 28:702–707. 2007. View Article : Google Scholar
|
|
35
|
Medeiros MA, França MS, Boileau G, Juliano
L and Carvalho KM: Specific fluorogenic substrates for neprilysin
(neutral endopeptidase, EC 3.4.24.11) which are highly resistant to
serine- and metalloproteases. Braz J Med Biol Res. 30:1157–1162.
1997. View Article : Google Scholar
|
